Detalhe da pesquisa
1.
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Nature;
618(7963): 144-150, 2023 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37165196
2.
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Nature;
611(7934): 155-160, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36289334
3.
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Nature;
615(7953): E23, 2023 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36894629
4.
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
Oncologist;
28(4): 351-357, 2023 04 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36745014
5.
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
Cancer;
127(23): 4393-4402, 2021 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34351646
6.
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Lancet Oncol;
21(6): 821-831, 2020 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32437664
7.
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Ann Surg Oncol;
27(4): 1180-1188, 2020 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31848819
8.
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
Oncologist;
21(7): 848-54, 2016 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27286787
9.
Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study.
Clin Cancer Res;
2024 May 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38767650
10.
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.
Pigment Cell Melanoma Res;
36(3-4): 314-320, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37039320
11.
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
J Clin Oncol;
40(10): 1059-1067, 2022 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34928709
12.
Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
J Immunother;
44(1): 9-15, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33290361
13.
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
Sci Transl Med;
13(608)2021 08 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34433638
14.
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Clin Cancer Res;
27(8): 2226-2235, 2021 04 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33509808
15.
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
Biol Blood Marrow Transplant;
16(7): 1005-17, 2010 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20167278
16.
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
J Clin Oncol;
38(15): 1655-1663, 2020 05 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32053428
17.
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
Clin Cancer Res;
26(13): 3193-3201, 2020 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32205463
18.
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
JAMA Oncol;
4(1): 98-101, 2018 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28817755
19.
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation.
Oncotarget;
8(62): 105000-105010, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29285228
20.
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.
J Natl Cancer Inst;
109(4)2017 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28040701